# NCT05142696 (NCT05142696)

> A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05142696
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Extensive Stage Small Cell Lung Cancer
- Interventions: [177Lu]Lu-DOTA-TATE; Atezolizumab; [68Ga]Ga-DOTA-TATE; Carboplatin; Etoposide
- Enrollment: 55
- Primary outcome: Phase 1b: Frequency of dose limiting toxicities (DLTs), Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to treatment discontinuation
- Primary outcome: Phase ll: Overall survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05142696